MedTrace Logo

Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis

NCT03097315 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2021-06-23

Study results available
· View outcomes & findings →

Summary

This open-label study is designed to evaluate the safety of suprachoroidally administered triamcinolone acetone injectable suspension, CLS-TA, in patients with non-infectious uveitis with and without macular edema.

Conditions

  • Uveitis
  • Uveitis, Posterior
  • Uveitis, Anterior
  • Uveitis, Intermediate
  • Panuveitis

Interventions

DRUG

4 mg CLS-TA Suprachoriodal Injection

CLS-TA, 40 mg/mL (4 mg in 100 microliters), will be administered as a single injection at 2 timepoints

Sponsors & Collaborators

  • Clearside Biomedical, Inc.

    lead INDUSTRY

Principal Investigators

  • Thomas Ciulla, MD · Clearside Biomedical, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-04
Primary Completion
2018-01-24
Completion
2018-01-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03097315 on ClinicalTrials.gov